Tenaya Therapeutics Inc (TNYA) Stock Price, Quote & News

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacet...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 825 6990

Website: www.tenayatherapeutics.com

Address:

171 Oyster Point Boulevard, Suite 500, South San Francisco, United States

waled_khal Apr. 8 at 10:32 AM

$TNYA

0 · Reply

Paulfrench Apr. 8 at 9:20 AM

$TNYA We're entering a critical zone. Either we manage to break into the cloud with a rising candle and increasing volume, in which case we should be pulled upwards, or we break away from the bottom of the cloud and we could see the price fall. I'm fairly confident because the 4-hour chart seems to indicate that buyers are consolidating the support at $0.67, but today's candle will certainly give us a clearer picture.

1 · Reply

waled_khal Apr. 8 at 12:31 AM

$TNYA

0 · Reply

waled_khal Apr. 7 at 11:19 PM

$TNYA

0 · Reply

blocktrade Apr. 7 at 5:34 PM

$TNYA ripping! Is there some news out there?

0 · Reply

waled_khal Apr. 7 at 4:49 PM

$TNYA

0 · Reply

Kmth01 Apr. 7 at 9:46 AM

$TNYA Immediate Resistance: The $0.80 - $0.85 range. Breaking above this could signal a trend reversal toward the $1.00 psychological level.

1 · Reply

americanpsycho42 Apr. 7 at 9:08 AM

$TNYA wow, hope this stays this way

1 · Reply

Paulfrench Apr. 7 at 5:59 AM

$TNYA Yesterday's candlestick suggests that yesterday's low will be broken (maybe we'll finally see that bounce back to $0.60 😆)... but let's be patient for a few more days or weeks.✊️

1 · Reply

blocktrade Apr. 6 at 8:00 PM

$TNYA nice low of the day close.

1 · Reply

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 9, 2026, 8:30 AM EDT - 4 weeks ago

Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Mar 5, 2026, 1:35 PM EST - 4 weeks ago

Tenaya Therapeutics Stock Jumps After New Alnylam Deal

ALNY

Mar 5, 2026, 9:10 AM EST - 4 weeks ago

Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

ALNY

Mar 5, 2026, 8:30 AM EST - 4 weeks ago

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

ALNY

Mar 2, 2026, 4:05 PM EST - 5 weeks ago

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

Jan 9, 2026, 8:30 AM EST - 3 months ago

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Dec 12, 2025, 1:56 PM EST - 4 months ago

Tenaya Stock Plunges After $60 Million Equity Offering

Dec 12, 2025, 12:16 AM EST - 4 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

Dec 11, 2025, 4:02 PM EST - 4 months ago

Tenaya Therapeutics Announces Proposed Public Offering

Dec 11, 2025, 4:01 PM EST - 4 months ago

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

Dec 11, 2025, 4:01 PM EST - 4 months ago

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

Nov 8, 2025, 11:25 AM EST - 5 months ago

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Nov 4, 2025, 5:30 PM EST - 5 months ago

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 4:05 PM EDT - 6 months ago

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 2, 2025, 4:05 PM EDT - 6 months ago

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Sep 18, 2025, 4:05 PM EDT - 7 months ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 31, 2025, 10:15 AM EDT - 7 months ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Aug 8, 2025, 8:00 AM EDT - 8 months ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 8 months ago

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:30 AM EDT - 8 months ago

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

May 13, 2025, 8:30 AM EDT - 11 months ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Apr 24, 2025, 2:07 PM EDT - 1 year ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:00 AM EST - 1 year ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Jan 13, 2025, 9:16 AM EST - 1 year ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Dec 16, 2024, 4:30 PM EST - 1 year ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Jun 27, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics Announces Research Leadership Updates

Jun 18, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

May 14, 2024, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 5:00 PM EDT - 2 years ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Mar 18, 2024, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Feb 26, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 8, 2024, 8:00 AM EST - 2 years ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Jan 3, 2024, 8:30 AM EST - 2 years ago

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:30 PM EST - 2 years ago

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Oct 26, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Oct 9, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Oct 2, 2023, 5:30 PM EDT - 2 years ago

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Sep 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Sep 21, 2023, 5:11 AM EDT - 2 years ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX SGHT TSBX

waled_khal Apr. 8 at 10:32 AM

$TNYA

0 · Reply

Paulfrench Apr. 8 at 9:20 AM

1 · Reply

waled_khal Apr. 8 at 12:31 AM

$TNYA

0 · Reply

waled_khal Apr. 7 at 11:19 PM

$TNYA

0 · Reply

blocktrade Apr. 7 at 5:34 PM

$TNYA ripping! Is there some news out there?

0 · Reply

waled_khal Apr. 7 at 4:49 PM

$TNYA

0 · Reply

Kmth01 Apr. 7 at 9:46 AM

$TNYA Immediate Resistance: The $0.80 - $0.85 range. Breaking above this could signal a trend reversal toward the $1.00 psychological level.

1 · Reply

americanpsycho42 Apr. 7 at 9:08 AM

$TNYA wow, hope this stays this way

1 · Reply

Paulfrench Apr. 7 at 5:59 AM

$TNYA Yesterday's candlestick suggests that yesterday's low will be broken (maybe we'll finally see that bounce back to $0.60 😆)... but let's be patient for a few more days or weeks.✊️

1 · Reply

blocktrade Apr. 6 at 8:00 PM

$TNYA nice low of the day close.

1 · Reply

blocktrade Apr. 6 at 7:40 PM

$TNYA 🐶💩

1 · Reply

Damage111 Apr. 6 at 5:27 PM

$TNYA

0 · Reply

Rolfthewild Apr. 6 at 5:22 PM

$TNYA Have a great Monday folks!

0 · Reply

waled_khal Apr. 6 at 12:15 PM

$TNYA https://finance.yahoo.com/sectors/technology/articles/exploring-us-high-growth-tech-113810910.html

0 · Reply

waled_khal Apr. 6 at 10:25 AM

$TNYA the stock has been active recently following several significant updates in late March, and the following context applies to today's trading: Positive Price Action: CNN Business indicated that as of the last close, the stock had experienced positive momentum, with a recent jump following a partnership deal with Alnylam Pharmaceuticals. Predictive Analysis: StockInvest.us projected a potential fair opening price for April 6, 2026, of approximately $ 0 . 6 8 3 , reflecting a minor forecasted change. Recent News Drivers: The stock has been trading based on news from late March regarding the positive interim data from the RIDGE™-1 clinical trial for TN-401. Upcoming Milestones: Yahoo Finance lists the next estimated earnings date as May 13, 2026

0 · Reply

americanpsycho42 Apr. 6 at 9:25 AM

$TNYA

0 · Reply

Mbuck17 Apr. 5 at 9:16 PM

$TNYA going to be a great year for TNYA. First up, the next data readout

1 · Reply

waled_khal Apr. 5 at 3:37 PM

$TNYA

0 · Reply

Damage111 Apr. 5 at 1:51 AM

$TNYA bout to buy in at 50,000 shares

2 · Reply

FUNKDCTR Apr. 3 at 3:02 AM

$TNYA Yes, I bought a position

0 · Reply

Rolfthewild Apr. 2 at 11:59 PM

$TNYA Historically on the Monday following easter stocks go through a retest of their current support levels but the week following is usually bullish or at least flat lined. In the current Geopolitical structure my guess is oil will rise monday other stocks will dip then oil will flatline unless new news follows. Tuesday will probably be a decent day for stocks as oil flatlines giving stocks some room to run and if any other news follows like the iran situation gets better stocks may end up flying. Keep in mind that Tenya has not shown Q2 results yet another catalyst that will be a wild card in the mix.

0 · Reply

Mbuck17 Apr. 2 at 9:29 PM

$TNYA Roughly 2 weeks until we hear they are presenting data at ASGCT

2 · Reply

Market Cap	143.22M
Revenue (ttm)	0.00
Net Income (ttm)	-90.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,815,500
Avg Vol	4,690,546
Day's Range	N/A - N/A
Shares Out	217.00M
Stochastic %K	26%
Beta	2.99
Analysts	Strong Sell
Price Target	$9.00